A total of 40 patients with B-CLL were investigated for CD5-triggered apoptosis and categorized as 20 resistant (group I) and 20 sensitive patients (group II). The densities of surface IgM (sIgM) and CD5 were lower in group I than group II, as were the percentages of CD79b þ , CD38 þ , and Zap70-expressing B cells. CD5 signaling was mediated through the BCR in group II B cells, as established by coimmunoprecipitation of CD5 and CD79a and tyrosine phosphorylation of CD79a. Following colocalization of CD5 and sIgM in membrane lipid rafts (LRs), Syk became associated with these molecules, whereas SHP-1 was uncoupled from CD5. Nonresponsiveness to CD5 crosslinking in group I was ascribed to three possible abnormalities, and defined as three subgroups of patients. In subgroups Ia and Ib, CD5 and sIgM colocalized within the LRs. SHP-1 remained attached to the BCR in subgroup Ia, but not in subgroup Ib, where signal transduction was associated with an excess of truncated CD79b. In subgroup Ic, CD5 and sIgM segregated into different LRs, resulting in no signaling of apoptosis.
Introduction
In B-CLL, accumulation of B cells reflects their resistance to apoptosis, and one of their salient features is the expression of CD5. 1 This leukemia comprises several entities, as indicated by the molecular complexity of the disease. 2 To confirm such a heterogeneity, our finding that CD5 crosslinking resulted in apoptosis of B cells 3 led us to examine CD5-induced apoptosis of B-CLL cells. The patients were classified into those resistant and those sensitive to CD5-triggered apoptosis. 4 At that time, we were unable to identify the reasons for such differences in the responses.
CD5 is associated with the CD79a/CD79b transduction partner of surface IgM (sIgM) in the vicinity of the BCR. Weak expression of sIgM has indeed been ascribed to a reduced expression of CD79b in B cells from more than 90% of the patients, due to mutations or alternative splicing of the CD79b gene. 5 In the latter case, the lack of exon 3 engenders shortened variants of the transcript and truncated (TR) isoforms of the protein. Since defective transduction has been reported, it has been suggested that intracellular signaling might need to be attenuated in B-CLL cells to allow survival in the face of constant self-antigen stimulation. 6 The simplest mechanism to prevent Bcell responses is to uncouple the BCR from tyrosine kinases, such as Syk and Lyn.
Lyn resides constitutively in membrane microdomains referred to as lipid rafts (LRs), enriched in ganglioside M1 (G M1 ), and clustering transduction proteins. Following crosslinking, a subset of BCRs partition into these LRs, 7 where CD79a/CD79b undergoes tyrosine (Y) phosphorylation by Lyn. Once recruited to phosphorylated CD79a/CD79b, Syk is also Y phosphorylated by Lyn, and the SHP-1 is displaced from the BCR. SHP-1, which is linked to the CD79a/CD79b subunits through CD5, negatively regulates signal transduction.
Our hypothesis that heterogeneous responses of malignant cells to CD5 engagement reflect differences in components of the signaling machinery was strengthened by the discovery that groups of B-CLL samples express different genes, most notably among those modulated during BCR signaling. 8 We provide evidence for the delivery of the CD5-induced apoptosis signal through CD79a/CD79b, and the translocation of this dimer to the LRs, along with CD5.
Materials and methods

Patients and controls
A total of 40 untreated patients fulfilling the criteria for the diagnosis of B-CLL 9 were enrolled in the study, and their informed consent was obtained according to our institutional review board. According to the Binet classification, 10 19 patients were stage A, 16 B, and five C. Blood was also obtained from 10 healthy volunteers, and tonsils from 14 children.
Antibodies and reagents
The antibodies (Abs) were from Beckman-Coulter (Villepinte, France), unless otherwise stated. F(ab') 2 UCHT2 anti-CD5 (gift from Professor P Beverley, London, UK) were crosslinked on the B-CLL cell surface with sheep F(ab') 2 anti-mouse F(ab') 2 (Jackson, West Grove, PA, USA). Anti-CD3, -CD4, -CD8 and -CD56 monoclonal Abs (mAbs) were used to enrich B cells, of which the purity was determined by phycoerythrin (PE)-or FITCanti-CD19, combined with FITC-anti-CD3 or PE-anti-CD5, respectively. FITC-rabbit F(ab') 2 anti-human IgM (Jackson) was associated with PE-anti-CD79b, anti-CD38, or anti-CD5 mAbs. B cells were permeabilized with 70% methanol prior to incubation with anti-Zap70 mAb (clone 29: Becton-Dickinson, Le Pont de Claix, France), or control IgG 1 , and their binding detected using FITC-sheep F(ab') 2 anti-mouse IgG (Jackson).
Cell lysates were precipitated with Leu-1 anti-CD5 mAb (Becton-Dickinson), which recognizes epitope 1 of CD5, whereas UCHT2, which recognizes epitope 2, 11 was used in Western blotting (WB) experiments. Anti-CD79a and antiphospho-Y (PY) mAbs (Santa-Cruz, Santa Cruz, CA, USA) were also used in immunoprecipitation (IP) experiments. Other reagents included anti-Lyn, anti-Syk, anti-PY (all from SantaCruz), anti-SHP-1 (Becton-Dickinson) and anti-CD79a mAbs. Biotinylated (biot) goat anti-mouse IgG and anti-rabbit IgG Abs, and HRP-streptavidin were from Amersham-Pharmacia (Saclay, France). Biot-cholera toxin B (CTB) is specific for G M1 (Sigma, St Louis, MO, USA), and its binding indicated the quality of isolated LRs. In the confocal microscopy (CM) studies, LRs were labeled with Alexa Fluor (AF) 594-CTB (Molecular Probes, Eugene, OR, USA), combined with FITC-goat F(ab') 2 anti-human IgM (Sigma) to detect translocation of sIgM into the LRs, or with FITC-sheep F(ab') 2 anti-mouse F(ab') 2 to crosslink the CD5 Ab. CD5 staining was also combined with rhodamine-anti-human IgM (Jackson) to demonstrate colocalization of CD5 and sIgM within the LRs.
Cell culture
Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll-Hypaque density gradient centrifugation. Those from patients were treated with a mixture of anti-CD3, -CD4, -CD8, and -CD56 mAbs, and the B cells negatively selected using immunomagnetic anti-mouse IgG Ab-coated beads (BioAdvance, Emerainville, France). Normal PBMCs and tonsillar cell suspensions were T-cell-depleted by two cycles of rosetting with sheep erythrocytes, and their B cells purified as above. This procedure yielded cell populations containing more than 96% B cells, of which, for the B-CLL patients, 77-99% expressed CD5, as shown by FITC-anti-CD19 and PE-anti-CD5 staining. FITCanti-CD3 staining revealed no residual T cells. 
CD79b transcript analysis
Since anti-CD79b mAbs from commercial sources cannot distinguish full-length (FL) and TR variants of CD79b, 12 RT-PCR was required. B cell mRNA was purified from two tonsillar and seven PBMC preparations, and from 13 CD5-resistant and eight CD5-sensitive randomly selected B-CLLs. Purified mRNA was incubated with oligo (dT) primers, deoxynucleotides mix and 200 U of RT from Moloney murine leukemia virus for 50 min at 421C, and 2 U of RNase H for another 20 min at 371C. Two pairs of primers were designed: for the CD79b gene, 5 
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0 -GTGACCATGGCCAGGCTGGCGTTGT-3 0 plus 5 0 -CCATC CATGTGTGGGGACGGATC-3 0 ; and for the GAPDH gene, 5 0 -CTTAGCACCCCTGGCCAAGG-3 0 plus 5 0 -CTTACTCCTTG GA-GGCCATG-3 0 . We obtained PCR products of 978 bp for FL-CD79b, 602 bp for its TR isoform, and 542 bp for GAPDH. PCR amplification was carried out, after the initial denaturation step for 4 min at 941C, and the addition of 2.5 U of Taq polymerase (Genaxis, St Cloud, France). The cycles were 30 s at 941C for denaturation, 60 s at 551C for annealing and 60 s at 721C for extension. A final 10-min extension cycle was performed with 35 cycles for CD79b and 30 for GAPDH. The intensity of each CD79b signal was normalized to that of GAPDH. Simultaneous amplification of two different transcripts in the same reaction provided a good estimate of their relative frequencies. The results were expressed as TR/FL ratios.
The same 21 patients were also evaluated by quantitative PCR, which was carried out in 10 ml mixtures containing 50 ng template cDNA, 1 Â Sybr s Green PCR master mix, and 500 nM of each primer. We used the 3 0 primer 5 0 -CCTCGCAGCGTC-ACTATGTCCTC-3 0 located in exon 6 for both isoforms of CD79b, and a pair of 5 0 primers: 5 0 -CACAGAGCTGCGAGT-CATGGGATTCAG-3 0 encompassing exons 2 and 3 of the FL isoform, or 5 0 -CGGTACCGGAATCCCAAAGGATTCAG-3 0 encompassing exons 2 and 4 of the TR isoform. The transcripts were cloned using the p-TrueBlue ligation kit. Amplification conditions consisted of one cycle at 501C for 2 min, one cycle at 951C for 10 min, and 40 cycles at 951C for 15 s and 601C for 1 min.
Determination of apoptosis
For a given patient, six wells of flat-bottomed 96-well plates (Nunc, Roskilde, Denmark) were coated with 50 mg/ml of sheep F(ab') 2 anti-mouse F(ab') 2 for 24 h at 41C, followed by 10 mg/ml of F(ab') 2 anti-CD5. Each of these six coated wells was arbitrarily paired with an uncoated well. Each sample was seeded at 5 Â 10 5 cells per well in 0.2 ml of RPMI medium 1640 with 10% FCS. Apoptosis was established through the binding of annexin V (AV). An aliquot of cells was stained with FITC-AV and propidium iodide (PI) after 24 h, and another after 36 h. Apoptotic cells were defined as those positive for AV but negative for PI, and necrotic cells as those positive for AV and PI. Significances of AV binding increases from six uncoated wells to six paired coated wells were determined using the Wilcoxon test for paired data: when P was 40.05, the patient's sample was assigned to the resistant group, and when P was o0.05, it was assigned to the sensitive group. Apoptosis was confirmed by cell morphology, enumeration of hypoploid cells and DNA fragmentation analysis, using methods that we have previously described. 3, 4 Immunoprecipitation and Western blotting Two aliquots of 1.5 Â 10 7 cells were left on ice for 30 min: the first one was incubated with 15 mg/ml UCHT2 F(ab') 2 and the second with medium alone. Both were washed and warmed to 371C for 5 min. Before IP with Leu-1 anti-CD5 or anti-CD79 mAb, the cells were treated for 30 min at 41C with 1% Brij 96 (Sigma) in lysis buffer (20 mM Tris-HCl, pH 7.5, 140 mM NaCl, 1 mM EDTA) with 1 mM PMSF, 10 mg/ml aprotinin, and 1 mM sodium orthovanadate. For IP with anti-PY, 1% Triton X-100 (Sigma) was substituted for Brij 96 to lyse the cells. All these preparations were centrifuged at 10 000 g for 10 min at 41C, and their supernatants cleared with protein G-coated beads, and with mouse IgG. Protein G was conjugated to magnetic beads (Miltenyi, Paris, France). A measure of 2 mg of the precipitating Ab was added to the lysates, along with 50 ml of protein Gmicrobeads. After incubation on ice for 30 min, the lysate was passed over a 'm column' placed in the magnetic field of the mMACS separator. This was rinsed 4 times with lysis buffer and once with 20 mM Tris-HCl. For SDS-PAGE, the column-bound proteins were incubated for 5 min with 20 ml of 951C hot 1 Â SDS gel loading buffer. IP proteins were then eluted using 50 ml of the same buffer. The proteins were resolved by 10% SDS-PAGE, blotted onto a PVDF membrane, and unbound sites blocked overnight with 1% gelatin. The strips were probed, developed with biot-goat anti-mouse IgG, plus HRP-streptavidin, and analyzed using the ECL detection system (AmershamPharmacia).
LR studies
To determine the role of LRs, the cells were incubated with 10 mM of methyl-b-cyclo-dextrin (MCD, Sigma) for 30 min at 371C in serum-free medium, before being cultured. The LRs were isolated based on their insolubility in nonionic detergents and buoyant density on sucrose gradient. Cells (7 Â 10 7 ) were washed with 25 mM Tris-HCl, 150 mM NaCl and 5 mM EDTA (TNE), and lysed for 30 min on ice in 1% Triton X-100 in TNE buffer with protease inhibitors. The lysates were centrifuged at 500 g. In all, 1 ml of the supernatant was mixed with 1 ml of 85% sucrose in TNE, overlaid with 3 ml of 35% sucrose and 1.5 ml of 5% sucrose in TNE, and centrifuged at 180 000 g for 12 h at 41C. The LR band was visible at the interface of 35 and 5% sucrose, and the nonraft membrane (NRM) fraction at the bottom of the tube. In all, 20 ml of each fraction was fractionated by SDS-PAGE, transferred onto PVDF membranes, blotted, and revealed with biot-goat anti-mouse IgG and HRP-streptavidin.
Three double-staining combinations were used for CM. In the first combination, B cells were incubated for 30 min on ice with AF 594-CTB to target red G M1 to the LRs and FITC-rabbit F(ab') 2 anti-human IgM to stain sIgM green, along with crosslinking F(ab') 2 mouse anti-CD5. One aliquot of cells was left at 41C as a control for nonactivation of CD5, and a second warmed to 371C for 5 min to allow activation through CD5. Both were washed and analyzed for double-stained cells with or without CD5 activation. In the second combination, B cells were incubated with AF 594-CTB and crosslinking F(ab') 2 mouse anti-CD5. One aliquot was left at 41C, and another warmed to 371C for 5 min. Both were incubated with FITC-sheep F(ab') 2 anti-mouse F(ab') 2 for 30 min on ice to induce crosslinking of CD5. In the third combination, B cells were incubated with rhodamine-rabbit F(ab') 2 anti-human IgM and crosslinking F(ab') 2 mouse anti-CD5. One aliquot was left at 41C, and, again, another warmed to 371C for 5 min. Both were incubated with FITC-sheep F(ab') 2 anti-mouse F(ab') 2 for 30 min on ice to visualize CD5. The cells were fixed in 3% paraformaldehyde for 10 min and centrifuged at 300 g onto microscope slides for analysis.
Statistical analysis
Results were expressed as means7s.e.m., and significances determined using the w 2 -test with Yates correction when required, and the paired Wilcoxon test and the Mann-Whitney U-test for unpaired data.
Results
CD5-induced apoptosis
To confirm that CD5 did not induce apoptosis in all samples, B cells from 40 patients were incubated with or without F(ab') 2 anti-CD5, and the CD5-added apoptosis measured after 24 and 36 h. Figure 1a shows that two groups of patients were delineated: no changes were seen with cells from 20 cases (group I), following CD5 crosslinking. In the remaining 20 (group II), this treatment increased the percentage of AV þ /PIÀ cells from 9.471.1% (spontaneous) to 23.972.3% at 24 h (P ¼ 0.0007), and from 16.271.6 to 32.871.8% at 36 h (P ¼ 0.0008), and those of AV þ /PI þ cells from 4.070.6 to 14.771.9% at 24 h (P ¼ 0.0007), and from 10.171.3 to 30.272.1% at 36 h (P ¼ 0.0004). Figure 1b shows a representative example of each group. AV-binding cells were increased as early as 18 h in culture in 15 group II patients, whereas this occurred later in another five, where differences became significant only after 36 h. These five patients were thus resistant at 24 h, and became sensitive to CD5-triggered apoptosis at 36 h. Apoptosis resistance or susceptibility to CD5-stimulation was stable for at least 3 years, as determined from serial blood samples from 12 group I and 14 group II patients. In addition to AV binding, cell morphology, enumeration of hypoploid cells, and DNA fragmentation analysis were used to confirm apoptosis in six group I and nine group II randomly selected patients. Advanced stage disease was less frequent in the resistant than in the sensitive group of patients: 14 were at stage A and six at Relationships between CD5-mediated apoptosis and cell markers The percentages of CD79b-and CD38-positive cells were also lower in group I than in group II (Table 1) . Three additional observations are worthy of note. Firstly, when patients with 20% or more B cells expressing CD38 were considered positive, 13 and those with less than 20% considered negative, fewer CD38-positive patients were seen in group I than in group II: 1/20 vs 16/20 (Po10 À5 ). Secondly, less Zap70 14 was expressed in group I than in group II (10.771.6 vs 65.675.7%, P ¼ 0.0013), and in CD38-negative than in CD38-positive group II cells (46.779.0 vs 78.973.5%, P ¼ 0.0064). Thirdly, the TR-CD79b/FL-CD79b ratios (supplementary Figure 1) were higher in group I than in group II (1.5570.23 vs 0.8170.05, P ¼ 0.0145). These results were verified by quantitative PCR: there were increasing amounts of TR products in group I B cells, whereas FL products predominated in group II B cells.
CD5-induced apoptosis requires an intact BCR signaling pathway
The suggestion, based on alterations in surface markers, that CD5 signaling involves CD79 was confirmed by IP. It appeared that CD5 was associated with CD79a, since these two molecules coprecipitated each other in CD5-stimulated B cells from four tonsils and seven group II patients (lanes 2 and 6, and lanes 4 and 8, respectively, in Figure 2a ). SHP-1 and Lyn were also linked to the BCR, provided CD5 was not engaged. In seven of these 13 patients, termed subgroup Ia, CD5 engagement did not displace SHP-1 from CD5 (compare lane 2 with 1, or lane 4 with 3 in Figure 2b) . In six patients, termed subgroup Ib, although SHP-1 was uncoupled from CD5 (compare lane 8 with 7, or lane 10 with 9), the cascade was not initiated (compare lane 12 with 11). This blockade was associated with an excess of the TR form of CD79b, relative to its FL variant (TR-CD79b/FL-CD79b ¼ 2.6070.70 in five subgroup Ib vs 1.1070.11 in six subgroup Ia, P ¼ 0.0139). This characteristic does not prove any inhibiting effect of the TR form of CD79b, 12 as there was no relationship between transcription of either variant and the membrane expression of the molecule: 6.972.3% of B cells expressed CD79b in subgroup Ia vs 2.971.3% in subgroup Ib. Upon CD5 stimulation, inspite of the segregation of CD5 and CD79a, Syk was not recruited. In seven patients, termed subgroup Ic, CD5 was not linked to CD79a, since these two molecules did not precipitate together (see lanes 14 and 13, and lanes 16 and 15) . Therefore, Syk was not recruited, SHP-1 not dissociated, and CD79a not Y-phosphorylated.
Involvement of LRs
Cholesterol-depleted LRs did not transduce the CD5 message, confirming that their role in initial signaling was critical. Owing to previous incubation of the cells with MCD, the percentage of 
Figure 2
Coimmunoprecipitation of BCR-associated molecules by anti-CD79a, anti-CD5, or anti-phosphotyrosine (PY) Abs, with and without prior engagement of CD5. (a) B cells from tonsils and group II patients. The strips were probed, the Abs revealed by goat anti-mouse IgG, plus HRP-streptavidin, and the blots developed using an ECL kit. (b) B cells from group I patients. Three subgroups were identified, and a representative example of each is presented. Cells are CD5-crosslinked ('yes') or not ('no'). (Figure 3a) . Following CD5 engagement, CD5 and CD79a were associated with G M1 , Syk and Zap70 recruited to the LRs, and SHP-1 left in the NRMs. Association of CD5 and sIgM within the LRs was then analyzed by CM (supplementary Figure 2) : overlay of the greenstained CD5, or green-stained sIgM, with the red-stained LRs was seen as yellow, demonstrating that CD5 and sIgM were within the same LRs. Next, B cells from the 20 group I patients were investigated for association of CD5 and the BCR relative to the LRs (Figure 3b) .
CD5-induced apoptosis in B-CLL
In subgoup Ia, CD79a and part of CD5 colocalized with LRs, but still SHP-1 was linked to CD5 (compare lane 2 with lane 1, and lane 4 with lane 3). In subgroup Ib, CD5 and CD79a were also together within the LRs, whereas SHP-1 was excluded (compare lane 6 with lane 5, and lane 8 with lane 7). In subgroup Ic, CD5 moved to LRs, but, based on the absence of Syk, no apoptosis message was delivered. Again (Figure 3c ), these findings were confirmed by CM examination of CD5 or sIgM, combined with the LR marker. In the seven subgroup Ic patients, CD5 and sIgM were not in the same LRs (lower 3 panels), although CD5 crosslinking encouraged CD5 (upper three panels), as well as sIgM (middle 3 panels), to partition into LRs. Hence, CD5 and sIgM segregated into different LRs.
Discussion
We have confirmed that two groups of B-CLL patients can be distinguished based on the response of their B cells to CD5 crosslinking. 4 Those from half of them resisted CD5-induced apoptosis (group I), while those from the remainder (group II) underwent more apoptosis with than without anti-CD5. One explanation could be differences in the numbers of CD5 and IgM molecules expressed by the different groups. Although the intensity of CD5 staining was higher in leukemic than in normal B cells, it was less so in group I than in group II. That of sIgM was lower in leukemic than in normal B cells, but more so in group I than in group II. The magnitude of the signal could thus be related to the number of CD5 molecules to which the Ab binds. Such differences could reflect the stages of differentiation or the levels of activation of the two categories of leukemic B cells, or, alternatively, that groups of leukemic cells responding differently in these experiments derive from separate normal CD5 þ B-cell populations that we have postulated to exist. 15 However, that this could explain differences in the responses to CD5 engagement was discounted by more in-depth analysis of CD5 in relation to other molecules. A high expression level of CD38 characterized those patients sensitive to CD5 crosslinking. This confirms the involvement of CD38 in BCRtriggered apoptosis, 12, 16 the behavior of CD38 and CD5 as inducible activation markers, 17 and the relationship between CD38 expression and early signaling through sIgM (Table 2) . 16 However, while the combined stimulation of B-CLL cells with anti-CD38 mAb and IL-2 has been shown to prolong survival, 18 CD5 crosslinking favors apoptosis. Both of these in vitro phenomena are associated with a more agressive course of the disease. However, the role of CD5 in leukemic cells in vivo is the central issue. Importantly, the common denominator of these two opposing observations is the competency of the BCR transducing machinery. Its effectiveness appears to be more 19 The IgVh gene mutational status is another prognostic indicator, such that patients with mutated IgVh genes survive longer than those using unmutated IgVh genes. 20 Patients with a severe course exhibit an intact sIgM transduction pathway 16 and possess CD38, suggesting that the ability to respond to external signals by prolonged survival of the cells contributes to poor prognosis. 20 Since CD5 is part of the BCR, and CD5-mediated apoptosis is associated with high CD38 expression, group II patients should use unmutated IgVh genes. Our finding of an elevated Zap70 expression in group II B cells is consistent with this prediction, since it correlates closely with unmutated IgVh genes. 21 Thus, aberrant expression of Zap70 could contribute to the high sensitivity of group II B cells to CD5-triggered apoptosis. This view is supported by the observation that CD5 is associated with Y-phosphorylated Zap70 in thymocytes. 22 We next established that the CD5-induced early signaling events proceeded through CD79a/CD79b by showing the mutual co-IP of CD5 and CD79, followed by Y phosphorylation of CD79a. Lyn was constitutively associated with the BCR, while, in response to CD5 crosslinking, Syk was recruited, and SHP-1 uncoupled from CD5. This is consistent with the dissociation of SHP-1 in CD5-negative B cells, following activation, 23 Furthermore, our studies on LRs showed that CD5, CD79a and Syk, but not SHP-1, cohabit in the LRs after CD5 activation. Indeed, for tonsil and group II B-CLL B cells, CD5, seen initially outside the LRs, moved there, along with CD79 and sIgM, while SHP-1 was left behind. Lyn phosphorylates CD79a/ CD79b, which then pushes Syk into being translocated to the LRs.
The results of the IP and LR studies warranted division of group I into three subgroups. In subgroup Ia, although CD5 and sIgM colocalize within the LRs, the apoptosis signal was not delivered: SHP-1 failed to separate from CD5 in the LRs, so that the proximity of SHP-1 facilitates inhibition of signaling. In contrast, SHP-1 was not found in LRs in subgroup Ib B cells, but this detachment of SHP-1 from CD5 was not sufficient for signal transduction. The percentage of CD79b-expressing B cells was higher in group II, compared with group I patients whose B cells contained more copies of the TR-CD79b transcript. This disproportionate expression of the TR form of CD79b, relative to its FL variant, was associated with the blockade. Such an excess in TR-CD79b was found in the non-responders in general, but more so in subgroup Ib patients. 5 Although the alternatively spliced variant might not be functional, this truncated molecule could act as an inert decoy, or as a protein with directly opposing functions. 12 In subgroup Ic, CD5 was separated from CD79. Following crosslinking, CD5 and BCR were targeted to LRs, but did not partition into the same LRs. The driving forces for LR localization are unknown, but evidence is accumulating for the existence of distinct subsets of LRs. 24 Transduction of the apoptosis signal from CD5 proceeds through CD79a/CD79b, which suggests a strong association of CD5 and sIgM within the same LRs.
We have established that CD5 and the BCR colocalize in LRs for the early signaling events leading to apoptosis, and described several mechanisms that could underlie defective signaling from CD5 in B-CLL cells. Since CD5-mediated signaling might be important for its effectiveness against B-CLL in vivo, our in vitro findings offer a rationale for the observation that not all patients 4 respond to treatment with anti-CD5 mAb.
